The DOI matches its Crossref record.
Protection Provided by Hepatitis B Vaccine in a Yupik Eskimo Population--Results of a 10-Year Study
Open accessAbstract
A hepatitis B virus vaccine demonstration project was conducted in southwest Alaska in 1981-1982 to determine the immunogenicity and efficacy of the vaccine. A total of 1630 susceptible persons in the Alaskan Native population were vaccinated with the recommended three-dose regimen of plasma-derived hepatitis B vaccine, and 94% demonstrated antibody to hepatitis B surface antigen (anti-HBs) at levels > or = 10 mIU/mL. After 10 years of follow-up, 76% of those immunized had anti-HBs levels > or = 10 mIU. During the 10 years following the first dose of vaccine, 13 study participants developed antibody to hepatitis B core antigen (10 vaccine responders, 3 nonresponders), and none developed sustained HBs positivity or had clinical hepatitis. These data suggest that immunization with hepatitis B vaccine continues to provide high levels of protection from clinical disease for at least 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epidemiology and Prevention of Hepatitis B Virus Infection
Hou, J., Liu, Z., & Gu, F. (2005) · International Journal of Medical Sciences · doi:10.7150/ijms.2.50 · Cited by 497
Shouval, D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00152-1 · Cited by 470
Are booster immunisations needed for lifelong hepatitis B immunity?
(2000) · The Lancet · doi:10.1016/s0140-6736(99)07239-6 · Cited by 455
Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection
Mahoney, F. J. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.351 · Cited by 446
The global impact of vaccination against hepatitis B: A historical overview
Zanetti, A. R., Van Damme, P., & Shouval, D. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.056 · Cited by 420
Bruce, M. G., Bruden, D., Hurlburt, D., Zanis, C., Thompson, G., Rea, L., Toomey, M., Townshend-Bulson, L., Rudolph, K., Bulkow, L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv748 · Cited by 322
Self-citationAntibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up
McMahon, B. J., Bruden, D. L., Petersen, K. M., Bulkow, L. R., Parkinson, A. J., Nainan, O., Khristova, M., Zanis, C., Peters, H., & Margolis, H. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00008 · Cited by 315
Self-citationHepatitis B and the Need for a Booster Dose
Leuridan, E., & Van Damme, P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir270 · Cited by 308
Pattyn, J., Hendrickx, G., Vorsters, A., & Van Damme, P. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa668 · Cited by 282
Guideline for Infection Control in Healthcare Personnel, 1998
Bolyard, E. A., Tablan, O. C., Williams, W. W., Pearson, M. L., Shapiro, C. N., Deitchman, S. D., & Hospital Infection Control Practices Advisory Committee (1998) · Infection Control & Hospital Epidemiology · doi:10.1086/647840 · Cited by 277
Keating, G. M., & Noble, S. (2003) · Drugs · doi:10.2165/00003495-200363100-00006 · Cited by 261
Epidemiology and prevention of hepatitis B virus infection
Kwon, S. Y., & Lee, C. H. (2011) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2011.17.2.87 · Cited by 171
Simons, B. C., Spradling, P. R., Bruden, D. J. T., Zanis, C., Case, S., Choromanski, T. L., Apodaca, M., Brogdon, H. D., Dwyer, G., Snowball, M., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw142 · Cited by 101
Zanoni, G., Contreas, G., Valletta, E., Gabrielli, O., Mengoli, C., & Veneri, D. (2015) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34309 · Cited by 23
Metadata
- Authors
- Wainwright, R. B., Bulkow, L. R., Parkinson, A. J., Zanis, C., & McMahon, B. J.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-03-01
- Volume
- 175
- Issue
- 3
- Pages
- 674-677
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2075192976
- Cited by
- 182
- References
- 0
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.